BRPI0518233A2 - terapia adjunta para depressço - Google Patents

terapia adjunta para depressço

Info

Publication number
BRPI0518233A2
BRPI0518233A2 BRPI0518233-6A BRPI0518233A BRPI0518233A2 BR PI0518233 A2 BRPI0518233 A2 BR PI0518233A2 BR PI0518233 A BRPI0518233 A BR PI0518233A BR PI0518233 A2 BRPI0518233 A2 BR PI0518233A2
Authority
BR
Brazil
Prior art keywords
carbon atoms
hydrogen
group
depression
atoms
Prior art date
Application number
BRPI0518233-6A
Other languages
English (en)
Inventor
Jonathan Sporn
Original Assignee
Sk Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Corp filed Critical Sk Corp
Publication of BRPI0518233A2 publication Critical patent/BRPI0518233A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dry Shavers And Clippers (AREA)

Abstract

TERAPIA ADJUNTA PARA DEPRESSçO. A presente invenção refere-se a um método de tratamento de depressão em um indivíduo compreendendo a etapa da administração de uma quantidade terapeuticamente eficaz de um antidepressivo convencional e, em adição, administração ao indivíduo de uma quantidade terapeutica- mente eficaz de um composto da Fórmula (1) ou um sal ou éster farmaceuticamente aceitável do mesmo onde Rx é um membro selecionado do grupo consistindo em hidrogênio, alquila inferior de 1 a 8 átomos de carbono, halogênio selecionado de F, Cl, Br e 1, alcóxi contendo 1 a 3 átomos de carbono, nitro, hidróxi, trifluormetila e tioalcóxi contendo 1 a 3 átomos de carbono; x é um inteiro de 1 a 3, contanto que R possa ser igual ou diferente quando x for 2 ou 3; R1 e R2 podem ser iguais ou diferentes um do outro e são independentemente selecionados do grupo consistindo em hidrogênio, alquila inferior de 1 a 8 átomos de carbono, ana, arilalquila, cicloalquila de 3 a 7 átomos de carbono; R1 e R2 podem ser unidos para formarem um heterociclo de 5 a 7 membros substituído com um membro selecionado do grupo consistindo em grupos hidrogênio, alquila e arila, onde o composto cíclico pode compreender 1 a 2 átomos de nitrogênio e O a 1 átomo de oxigênio, onde os átomos de nitrogênio não estão diretamente conectados uns aos outros ou com o átomo de oxigênio.
BRPI0518233-6A 2004-10-28 2005-10-26 terapia adjunta para depressço BRPI0518233A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62304404P 2004-10-28 2004-10-28
PCT/US2005/038804 WO2006050037A1 (en) 2004-10-28 2005-10-26 Adjunctive therapy for depression

Publications (1)

Publication Number Publication Date
BRPI0518233A2 true BRPI0518233A2 (pt) 2008-11-11

Family

ID=35966035

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518233-6A BRPI0518233A2 (pt) 2004-10-28 2005-10-26 terapia adjunta para depressço

Country Status (12)

Country Link
US (1) US8729120B2 (pt)
EP (1) EP1819328A1 (pt)
JP (1) JP2008518921A (pt)
KR (1) KR20070083826A (pt)
CN (1) CN101132787A (pt)
AU (1) AU2005302589B2 (pt)
BR (1) BRPI0518233A2 (pt)
CA (1) CA2587481A1 (pt)
IL (1) IL182746A (pt)
MX (1) MX2007005172A (pt)
RU (1) RU2007119648A (pt)
WO (1) WO2006050037A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1890684B1 (en) 2005-06-08 2013-08-14 SK Biopharmaceuticals Co., Ltd. Treatment of sleep-wake disorders
ES2344469T3 (es) * 2005-06-22 2010-08-27 Sk Holdings Co., Ltd. Tratamiento de disfuncion sexual.
EP2081648A2 (en) * 2006-10-30 2009-07-29 Janssen Pharmaceutica, N.V. Carbamate compounds for use in treating depression
KR20120098578A (ko) 2009-06-22 2012-09-05 에스케이바이오팜 주식회사 피로의 치료 또는 예방 방법
BR112012010670A2 (pt) 2009-11-06 2016-04-12 Sk Biopharmaceuticals Co Ltd métodos para tratamento de distúrbio de défict de atenção/hiperatividade
EP2496227B1 (en) * 2009-11-06 2019-05-22 SK Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
US9610274B2 (en) * 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
CA2905457A1 (en) 2013-03-13 2014-10-09 Aerial Biopharma, Llc Treatment of cataplexy
JP2016530240A (ja) * 2013-07-12 2016-09-29 ジャズ ファーマスティカルズ インターナショナル スリー リミテッドJazz Pharmaceuticals International Iii Limited 禁煙の促進
CA2917702A1 (en) 2013-07-18 2015-01-22 Jazz Pharmaceuticals International Iii Limited Treatment for obesity
TWI698415B (zh) 2014-02-28 2020-07-11 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
US10888542B2 (en) 2014-02-28 2021-01-12 Sk Biopharmaceuticals Co., Ltd. Aminocarbonylcarbamate compounds
JP6466792B2 (ja) * 2015-07-03 2019-02-06 エスケー バイオファーマスティカルズ カンパニー リミテッド 注意欠陥/多動性障害(adhd)の治療方法
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
MY197630A (en) 2016-09-06 2023-06-29 Sk Biopharmaceuticals Co Ltd Solvate form of (r)-2-amino-3-phenylpropyl carbamate
ES2964943T3 (es) 2016-10-06 2024-04-10 Axsome Malta Ltd Compuestos de carbamoilfenilalaninol para uso médico
BR112019025286A2 (pt) 2017-06-02 2020-06-23 Jazz Pharmaceuticals Ireland Limited Métodos e composições para tratamento de sonolência excessiva
JP7366002B2 (ja) 2017-07-31 2023-10-20 ジャズ ファーマシューティカルズ アイルランド リミテッド カルバモイルフェニルアラニノール類縁体およびその使用
CN110655500B (zh) * 2018-06-28 2020-12-08 浙江京新药业股份有限公司 氨基甲酸酯衍生物及其制备方法和用途
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
KR20260033050A (ko) 2023-06-29 2026-03-10 액섬 테라퓨틱스, 인크. 수유 여성에게 솔리암페톨을 투여하는 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100197892B1 (ko) * 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
KR0173862B1 (ko) 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
US5756817C1 (en) * 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
EP1309325A1 (en) * 2000-08-02 2003-05-14 Ortho-McNeil Pharmaceutical, Inc. Anticonvulsant derivatives useful for the treatment of depression
CN1989968B (zh) * 2002-12-27 2011-05-11 大塚制药株式会社 用于治疗情绪障碍的喹诺酮衍生物和5-羟色胺再摄取抑制剂
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo

Also Published As

Publication number Publication date
KR20070083826A (ko) 2007-08-24
RU2007119648A (ru) 2008-12-10
CA2587481A1 (en) 2006-05-11
WO2006050037A1 (en) 2006-05-11
AU2005302589A1 (en) 2006-05-11
JP2008518921A (ja) 2008-06-05
US20080039529A1 (en) 2008-02-14
CN101132787A (zh) 2008-02-27
IL182746A (en) 2014-08-31
EP1819328A1 (en) 2007-08-22
AU2005302589B2 (en) 2010-09-16
IL182746A0 (en) 2007-09-20
US8729120B2 (en) 2014-05-20
MX2007005172A (es) 2007-06-22

Similar Documents

Publication Publication Date Title
BRPI0518233A2 (pt) terapia adjunta para depressço
TW200716084A (en) Methods for treating sleep-wake disorders
BR0312999A (pt) Compostos, composições farmacêticas, método para aumentar a cognição, de tratamento, de inibição da atividade de enzima pde4 em um paciente
WO2007095174A3 (en) Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated diseases or conditions
BRPI0409227C1 (pt) composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)
HUP0203971A2 (hu) Imidazoimidazolok és -triazolok mint gyulladásellenes szerek és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
BRPI0417687A (pt) derivados de benzenossulfonilamino-piridin-2-ila e compostos relacionados como inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1 (11-beta-hsd-1) para o tratamento de diabetes e obesidade
BRPI0818193B8 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0718966B8 (pt) composto, composição farmacêutica, inibidor plk1 e agente antitumoral
ATE485258T1 (de) Glycyrrhetinsäurederivate und ihre verwendung zur herstellung eines medikaments zur hemmung der 11- beta-hydroxysteroid dehydrogenase
MXPA05008619A (es) Derivados novedosos de 2-piridincarboxamida.
EA200401609A1 (ru) Лекарственное средство для лечения диабета
BR0317705A (pt) Composto, formulação farmacêutica, uso de um composto, método de tratamento de doenças ou condições, e, processo para a preparação de compostos
HUP0402376A2 (hu) Imidazol-4-karboxamid-származékok, előállításuk és az ezeket tartalmazó, elhízás kezelésére alkalmas gyógyszerkészítmények
RU2012123154A (ru) Способы лечения синдрома фибромиалгии
WO2003004485A1 (fr) Composes heterocycles a 5 chainons condenses avec un benzo, leur procede de preparation et leur utilisation
RU2012155118A (ru) Способы лечения биполярного расстройства
NZ330973A (en) Azolobenzazepine derivatives as neurologically active agents
ATE279192T1 (de) Die verwendung eines benzimidazoles zur herstellung eines medikamentes zur krebsvorbeugung
BRPI0406780A (pt) Novos compostos
MY145066A (en) Methods for treating sexual dysfunction
BR9912612A (pt) Composto de maleimida dissubstituìdo e seu usofarmacêutico
BR0310032A (pt) Derivados de benzoxazina como moduladores de 5-ht6 e usos dos mesmos
MA31674B1 (fr) Dérivés de 7 -alkynyl-1,8-naphthyridones, leur préparation et leur application en thérapeutique
BRPI0408248A (pt) derivados azabicìclicos de piridiloximetila e de benzisoxazol

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: SK HOLDINGS CO., LTD. (KR)

Free format text: ALTERADO DE: SK CORPORATION

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B25A Requested transfer of rights approved

Owner name: SK BIOPHARMACEUTICALS CO., LTD. (KR)

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL